Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All tixagevimab/cilgavimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchTixagevimab/cilgavimabTixagev../c.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -1% Improvement Relative Risk Ventilation -96% ICU admission -210% Hospitalization 53% Symp. case 29% unadjusted Tixagevimab/c..  Sindu et al.  Prophylaxis Is prophylaxis with tixagevimab/cilgavimab beneficial for COVID-19? Retrospective 546 patients in the USA (December 2021 - August 2022) Higher ventilation (p=0.58) and ICU admission (p=0.33), not sig. c19early.org Sindu et al., Transplantation Direct, May 2023 Favors tixagevimab/ci.. Favors control

Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection

Sindu et al., Transplantation Direct, doi:10.1097/txd.0000000000001485
May 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
37th treatment shown to reduce risk in May 2022
 
*, now known with p = 0.00002 from 15 studies, recognized in 30 countries. Efficacy is variant dependent.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Retrospective 546 lung transplant recipients, 203 receiving tixagevimab/cilgavimab, and 343 out of state or declining treatment, showing a trend towards lower incidence of cases, but no significant difference in clinical outcomes.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.1 Planas, BA.5, BA.2.75, XBB Haars, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.1 Pochtovyi.
risk of death, 1.5% higher, HR 1.01, p = 0.99, treatment 2 of 17 (11.8%), control 2 of 17 (11.8%), propensity score matching, Cox proportional hazards.
risk of mechanical ventilation, 95.8% higher, HR 1.96, p = 0.58, propensity score matching, Cox proportional hazards.
risk of ICU admission, 209.6% higher, HR 3.10, p = 0.33, propensity score matching, Cox proportional hazards.
risk of hospitalization, 53.2% lower, HR 0.47, p = 0.17, propensity score matching, Cox proportional hazards.
risk of symptomatic case, 28.9% lower, RR 0.71, p = 0.14, treatment 24 of 203 (11.8%), control 57 of 343 (16.6%), NNT 21, unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sindu et al., 12 May 2023, retrospective, USA, peer-reviewed, median age 67.4, 7 authors, study period December 2021 - August 2022. Contact: sofya.tokman@dignityhealth.org.
This PaperTixagev../c..All
Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection
MD Devika Sindu, MD Deepika Razia, RN, MSN Katherine Grief, MD Lauren Cherrier, MD Ashraf Omar, MD Rajat Walia, MD Sofya Tokman
Transplantation Direct, doi:10.1097/txd.0000000000001485
I nfection with the severe acute respiratory syndrome coro- navirus 2 (SARS-CoV-2) and the resulting COVID-19 have led to significant morbidity and mortality among solid organ transplant recipients since the start of the pandemic. 1 Mutations in the viral spike protein have led to the emergence of numerous variants, with the Omicron variant and its sublineages dominating since December 2021. 2, 3 Although the rates of hospitalization and in-hospital mortality fell in the general population during the Omicron surge, the morbidity and mortality among solid organ transplant recipients remained disproportionately high. 4, 5 Vaccination is the cornerstone of prevention of severe COVID-19 in the general population; however, the immune response to vaccination among solid organ transplant recipients is often inadequate, leaving them susceptible to severe illness. A study of 658 solid organ transplant recipients, including 71 lung transplant recipients (LTRs), showed that only 39% of LTRs developed an antibody response after 2 doses of a SARS-CoV-2 mRNA vaccine. 6 Furthermore, although a third vaccine dose improved the humoral response Lung Transplantation Background. Lung transplant recipients (LTRs) have an increased risk of COVID-19-related morbidity and mortality. Tixagevimab-cilgavimab (tix-cil) is a long-acting monoclonal antibody combination granted Emergency Use Authorization approval by the US Food and Drug Administration for COVID-19 pre-exposure prophylaxis (PrEP) in immunocompromised patients. We sought to determine whether tix-cil 300-300 mg reduced the incidence and disease severity of severe acute respiratory syndrome coronavirus 2 infection in LTRs during the Omicron wave. Methods. We performed a retrospective, single-center cohort study of LTRs who had received a COVID-19 diagnosis between December 2021 and August 2022. We compared baseline characteristics and clinical outcomes after COVID-19 between LTRs who received tix-cil PrEP and those who did not. We then conducted propensity-score matching based on baseline characteristics and therapeutic interventions and compared clinical outcomes between the 2 groups. Results. Of 203 LTRs who received tix-cil PrEP and 343 who did not, 24 (11.8%) and 57 (16.6%), respectively, developed symptomatic COVID-19 (hazard ratio [HR], 0.669; 95% confidence interval [CI], 0.415-1.079; P = 0.099). The hospitalization rate of LTRs with COVID-19 during the Omicron wave trended lower in the tix-cil group than in the non-tix-cil group (20.8% versus 43.1%; HR, 0.430; 95% CI, 0.165-1.118; P = 0.083). In propensity-matched analyses, 17 LTRs who received tix-cil and 17 LTRs who did not had similar rates of hospitalization (HR, 0.468;
References
Adjei, Hong, Molinari, Mortality risk among patients hospitalized primarily for COVID-19 during the Omicron and Delta variant pandemic periods -United States, MMWR Morb Mortal Wkly Rep
Austin, An introduction to propensity score methods for reducing the effects of confounding in observational studies, Multivariate Behav Res
Benotmane, Gautier, Perrin, Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses, JAMA
Benotmane, Velay, Gautier-Vargas, Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients, Am J Transplant
Boyarsky, Werbel, Avery, Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients, JAMA
Bruel, Hadjadj, Maes, Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies, Nat Med
Centers, Services, COVID-19 monoclonal antibodies
Dauriat, Beaumont, Nguyen, Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study, Eur Respir J
Fisher, Schlauch, Mulloy, Outcomes of COVID-19 in hospitalized solid organ transplant recipients compared to a matched cohort of non-transplant patients at a national healthcare system in the United States, Clin Transplant
Focosi, Casadevall, A critical analysis of the use of cilgavimab plus tixagevimab monoclonal antibody cocktail (Evusheld™) for COVID-19 prophylaxis and treatment, Viruses
Heldman, Kates, Safa, UW COVID-19 SOT Study Team. COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: a comparative analysis from a multicenter study, Am J Transplant
Iketani, Liu, Guo, Antibody evasion properties of SARS-CoV-2 Omicron sublineages, Nature
Keam, Tixagevimab + cilgavimab: first approval, Drugs
Kertes, Shapiro, David, Engel-Zohar, Association between AZD7442 (tixagevimab-cilgavimab) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality, Clin Infect Dis
Kneidinger, Hecker, Bessa, Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a nationwide German study, Infection. 2022 Sept
Lakens, Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs, Front Psychol
Levin, Ustianowski, Wit, Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19, N Engl J Med
Meng, Abdullahi, Ferreira, Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity, Nature
Messika, Eloy, Roux, COVID-19 in lung transplant recipients, Transplantation
Najjar-Debbiny, Gronich, Weber, Effectiveness of Evusheld in immunocompromised patients: propensity score-matched analysis, Clin Infect Dis
Nguyen, Flahault, Chavarot, AP-HP-Centre Monoclonal Antibodies Working Group. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients, Clin Microbiol Infect
Ordaya, Beam, Yao, Characterization of early-onset severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients who received tixagevimab-cilgavimab prophylaxis, Open Forum Infect Dis
Pereira, Mohan, Cohen, COVID-19 in solid organ transplant recipients: initial report from the US epicenter, Am J Transplant
Saez-Giménez, Berastegui, Barrecheguren, COVID-19 in lung transplant recipients: a multicenter study, Am J Transplant
Vanblargan, Errico, Halfmann, An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies, Nat Med
Zost, Gilchuk, Case, Potently neutralizing and protective human antibodies against SARS-CoV-2, Nature
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit